IRIS
PEVIANI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 742
EU - Europa 519
AS - Asia 276
Totale 1.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 736
CN - Cina 258
IE - Irlanda 189
IT - Italia 99
FI - Finlandia 64
UA - Ucraina 61
DE - Germania 42
SE - Svezia 23
BE - Belgio 17
GB - Regno Unito 13
CA - Canada 6
FR - Francia 6
IN - India 5
SG - Singapore 4
VN - Vietnam 3
JP - Giappone 2
MY - Malesia 2
NL - Olanda 2
CZ - Repubblica Ceca 1
GR - Grecia 1
IR - Iran 1
KR - Corea 1
RU - Federazione Russa 1
Totale 1.537
Salva come PNG Salva come JPEG
Città #
Dublin 189
Chandler 175
Jacksonville 80
Nanjing 77
Ann Arbor 54
Pavia 49
Ashburn 46
Beijing 38
Princeton 35
Lawrence 34
Wilmington 31
Nanchang 29
Helsinki 28
Medford 23
Piscataway 19
Hebei 18
New York 18
Shanghai 18
Jiaxing 15
Changsha 14
Boardman 13
Brussels 13
Shenyang 12
Tianjin 12
Woodbridge 9
Chicago 8
Seattle 8
Milan 7
Falls Church 6
Los Angeles 6
Washington 6
Hangzhou 5
Toronto 5
Des Moines 4
Piemonte 4
Pune 4
Tappahannock 4
Fairfield 3
Auburn Hills 2
Calusco d'Adda 2
Casorate Primo 2
Dong Ket 2
Jinan 2
Ningbo 2
Norwalk 2
Reggio Emilia 2
Rockville 2
Torino 2
Turin 2
Amsterdam 1
Augsburg 1
Borås 1
Brno 1
Changteh 1
Gallarate 1
Hanoi 1
Houston 1
Jinhua 1
Kunming 1
Lanzhou 1
Munich 1
Nanyang 1
Nuremberg 1
Prineville 1
Qingdao 1
Redwood City 1
Shaoxing 1
Singapore 1
Suizenji 1
Tokyo 1
Verona 1
West Palm Beach 1
Zhengzhou 1
Totale 1.165
Salva come PNG Salva come JPEG
Nome #
Studies on the Enantiomers of RC-33 as Neuroprotective Agents: Isolation, Configurational Assignment, and Preliminary Biological Profile 86
(R)-RC-33 as Promising Neuroprotective Agent Acting as Sigma1 Receptor Agonist 79
Identification of RC-33 as a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-scale synthesis, physicochemical characterization and in vitro metabolic stability. 72
Chemical, pharmacological, and in vitro metabolic stability studies on enantiomerically pure RC-33 compounds, promising neuroprotective agents acting as sigma1 receptor agonists. 71
In Situ Agar – Carbomer Hydrogel Polycondensation:a Chemical Approach to Regenerative Medicine 70
A step forward in the sigma enigma: a role for chirality in the sigma1 receptor- ligand interaction? 69
Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase. 67
Identification of a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. 63
Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome. 60
Development of easy-to-use reverse-phase liquid chromatographic methods for determining PRE-084, RC-33 and RC-34 in biological matrices. The first step for in vivo analysis of sigma1 receptor agonists. 54
Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084,in a mouse model of motor neuron disease not linked to SOD1 mutation 50
Lack of changes in the PI3K/AKT survival pathway in the spinal cord motor neurons of a mouse model of familial amyotrophic lateral sclerosis. 50
Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. 49
Use of arylalkanolamines as sigma-1 receptor antagonists 49
Studies on the enantiomers of RC-33, promising neuroprotective agents acting as sigma1 receptor agonists. Isolation, configurational assignment and biological profile 48
COMPOSITIONS AND METHODS FOR TARGETING CELLS 47
Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis 45
Chemical, pharmacological and in vivo pharmacokinetic studies on enantiomerically pure RC-33 compounds, promising neuroprotective agents acting as sigma1 receptor agonists 44
Heterogeneity of neuroinflammatory responses in amyotrophic lateral sclerosis: A challenge or an opportunity? 41
Sigma1 Receptor Agonists in motor dysfunction pathologies treatment – a medicinal chemistry perspective 40
Neurophysiological characterisation of the g93a ALS rat model 38
COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM 37
Toward the identification of neuroprotective agents: G-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist 36
Hydrazone linked doxorubicin-PLA prodrug nanoparticles with high drug loading 34
Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells 30
Bitopic Sigma 1 Receptor Modulators to Shed Light on Molecular Mechanisms Underpinning Ligand Binding and Receptor Oligomerization 29
Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. 28
Lipophilic dye-compatible brain clearing technique allowing correlative magnetic resonance/high-resolution fluorescence imaging in rat models of glioblastoma 28
Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System 27
Synthesis and characterization of a “clickable” pbr28 tspo-selective ligand derivative suitable for the functionalization of biodegradable polymer nanoparticles 27
T1-weighted dynamic contrast-enhanced MRI is a noninvasive marker of epidermal growth factor receptor VIII status in cancer stem cell-derived experimental glioblastomas 20
Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release 19
Metallothioneins are neuroprotective agents in lysosomal storage disorders 16
Fast deep learning reconstruction techniques for preclinical magnetic resonance fingerprinting 14
Simultaneous flow cytometric characterization of multiple cell types retrieved from mouse brain/spinal cord through different homogenization methods 13
Novel S1R agonists counteracting NMDA excitotoxicity and oxidative stress: A step forward in the discovery of neuroprotective agents 10
null 9
An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model 8
Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain 6
Totale 1.583
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.454
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020310 84 108 1 14 3 12 2 15 5 20 31 15
2020/2021164 14 12 4 14 3 18 1 41 17 18 16 6
2021/2022173 7 2 8 3 5 7 7 15 16 6 18 79
2022/2023529 56 54 1 33 43 58 0 29 231 2 12 10
2023/2024230 27 30 7 10 22 59 5 18 2 10 36 4
2024/202516 16 0 0 0 0 0 0 0 0 0 0 0
Totale 1.583